Neoplasms

Symptoms and General Pathology

All Conditions

Neoplasm, Residual

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Azacitidine

Antimetabolites

Enzyme Inhibitors

chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.

azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.

chidamide and azacitidine

WENG jian yu, M.D.

Ling Wei, M.D.

acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.

Investigators proposed Chidamide combined with azacitidine as the prospective treatment for MRD-positive AML patients before and after transplantation, hoping to reduce the recurrence rate of transplantation and improve the transplantation effect. The efficacy and safety of the method will be verified by this clinical study.

A Study of Chidamide With AZA in MRD Positive AML After Transplant

T cell receptor excision circles (TRECs) are released upon rearrangement of the T cell receptor.

Grade 1 to Grade 4 ,according to Common Terminology Criteria for Adverse Events, versions 5.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Chidamide With AZA in MRD Positive AML After Transplant	NCT06066905	AML, Adult Minimal Residua...	chidamide and a...	18 Years -	Guangdong Provincial People's Hospital
A Study of Chidamide With AZA in MRD Positive AML After Transplant	NCT06066905	AML, Adult Minimal Residua...	chidamide and a...	18 Years -	Guangdong Provincial People's Hospital

Spots Global Cancer Trial Database for chidamide and azacitidine